组织型纤溶酶原激活剂及其抑制物的变化与冠心病的关系被引量：9

Changes of Fbrinolytic Parameters in Coronary Heart Disease

下载PDF

导出

摘要目的:观察冠心病患者纤溶活性的变化及其在冠心病发病中的作用,探讨其临床意义。方法:用酶联免疫双抗夹心(ELISA)法测定58例冠心病患者血浆中组织型纤溶酶原激活剂(t-PA)及纤溶酶原激活抑制物-1(PAI-1)抗原含量,反映纤溶-抗纤溶活性的变化,并对冠心病患者组与对照组纤溶指标进行不同性别间的比较。结果:急性心肌梗死、不稳定心绞痛患者PAI-1的含量、PAI-1/t-PA比值明显高于对照组,且急性心肌梗死患者PAI-1的含量较不稳定心绞痛患者显著为高。但t-PA在急性心肌梗死、不稳定心绞痛患者均无显著降低。患者组及对照组不同性别间纤溶及抗纤溶水平均未见有显著差异。结论:血栓性疾病与纤溶系统的异常有密切关系。纤溶系统活性的变化及纤溶-抗纤溶的平衡失调在缺血性心脏病的发生、发展中起着重要作用。 Objective: To explore the alterations of fibrinolytic parameters with coronary heart disease(CHD) to elucidate the mechanism of CHD and its clinical significance. Methods: A series of fibrinolytic parameters were measured among 58 cases of CHD using ELISA , including tissue-type plasminogen activator(t-PA) and plasmino-gen activator inhibitor-1(PAI-1). Results: The plasma level of PAl-1 and PAl-1/t-PA were elevated significantly in patients with AMI and UAP than in controls ,PAl1 were higher in patients with AMI than with USP( P < 0. 01). Plasma t-PA antigen was not decreased in patients with AMI and USP. The difference of parameters between male and female was not found. Conclusion: Our results suggest that the alteration of fibrinolytic systems play an important role in the pathogenesis, developing and prognosis of CHD.

作者杨林花董春霞王凤芝刘秀娥侯丽虹马艳萍

机构地区山西医科大学第二医院

出处《血栓与止血学》 2004年第1期8-10,共3页 Chinese Journal of Thrombosis and Hemostasis

基金山西省归国留人员基金(200051)资助山西省教委基金(99035)资助

关键词组织型纤溶酶原激活剂抑制物冠心病纤溶酶原激活抑制物-1 心肌梗死 Coronary heart disease Tissue-type plasminogen activator Plasminogen activator ingibitor-1

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献15

1[1]Lusis AJ. Atherosclerosis[J].Nature,2000,407(6801):233～241.
2[2]Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation[J]. Blood, 1987,70(5): 1645～1653.
3国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(2):75-75.
4[5]Panchenko E, Bobrovolsky A, Davletor K, et al. Di-dimer and fibrinolysis in patients with various degrees of artherosclerosis[J]. Eur Heart J, 1995, 16(1):38～42.
5[6]Herren T, Stricker H, Haeberli A. Fibrin formation and degradation in patients with arteriosclerotic disease[J]. Circulation 1994,90(6): 2679～2686.
6[7]Aznar J, Estelles A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases[J]. Haemostasis,1994,24(4): 243～251.
7[8]Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities[J]. Circulation,1996,94(9): 2057～2063.
8[9]Chien KL, Lee YT, Sung FC, et al. Hyporinsulinemia and related atherosclerotic risk factors in the population at cardiovascular risk: a communitybased study[J]. Clin Chem, 1999 45(6 Pt 1 ): 838～846.
9[10]Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view[J]. Thromb Haemost,2001,86(1): 366～373.
10[11]Caputo M, Mantini G, Floriani I, et al. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary,epiaortic and peripheral occlusive attery disease[J]. Eur Heart J, 1996, 17(9):1329～1336.